MALARIA

疟疾

• 批准号: 7719093
• 负责人: CHOUKRI BEN MAMOUN
• 金额: $ 0.25万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719093
• 关键词: Acute; Admission activity; Africa; Antimalarials; Area; Biology; Blood; Cessation of life; Child; Chloroguanide; Chloroquine; Chloroquine resistance; Clinical; Computer Retrieval of Information on Scientific Projects Database; Condition; Consultations; Development; Diagnosis; Drug resistance; Economics; Effectiveness; Erythrocytes; Funding; Future; Grant; Hospitals; Human; Institution; International; Laboratories; Link; Malaria; Mefloquine; Numbers; Outcome; Outpatients; Parasites; Parasitic Diseases; Pathway interactions; Pharmaceutical Preparations; Plasmodium falciparum; Prophylactic treatment; Quinine; Research; Research Personnel; Resources; Sampling; Social Development; Source; Staging; Symptoms; United States; United States National Institutes of Health; cost; environmental change; pathogen; vaccine development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Malaria is by far the world's most important tropical parasitic disease. It causes clinical illness in 300 million to 500 million people, 1.5 million to 2.7 million of whom die. Sub-saharian Africa remains the most malarious region in the world with ninety percent of cases and deaths, mostly among children, In this region, about 30% of outpatient consultations and up to 20% hospital admissions are due to malaria. This causes major disturbance in economic and social development. Malaria cases in the United States are linked to international tourism with about one thousand cases diagnosed and treated each year. Since the mid-1950's malaria prophylaxis has relied mostly on chloroquine because of its effectiveness and, notably its low cost. Chloroquine resistance has become widespread in different parts of the world. Mefloquine and quinine have been used extensively in areas of resistance to chloroquine, and proguanil for prophylaxis and treatment, but resistance to these drugs is becoming a substantial problem. The need for more efficacious and less toxic agents, particularly rational drugs that exploit pathways and targets unique to the parasite, is therefore acute. Plasmodium falciparum is an important intraerythrocytic protozoan pathogen, responsible for the most severe form of human malaria. The parasite undergoes a number of developmental stages in the human host and multiplies asexually in the red blood cell to effect its clinical symptoms and lethal outcome. Research in my laboratory focuses on how the malaria parasite responds to changing environmental conditions. Maintaining the parasite in culture is an essential step in our research toward understanding the basic biology of this parasite and future development of a vaccine or new antimalarial drugs. The GCRC supports the study by by drawing blood and transporting the sample to the research lab.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 到目前为止，疟疾是世界上最重要的热带寄生虫病。 它导致3亿至5亿人，其中150万至270万人死亡。 非洲以下非洲仍然是世界上最卑鄙的地区，案件和死亡人数百分之九十，主要是在该地区的儿童中，大约30％的门诊咨询，高达20％的医院入院是由于疟疾造成的。 这会引起经济和社会发展的重大干扰。 美国的疟疾病例与国际旅游业有关，每年约有一千例被诊断和治疗的病例。 自1950年中期的疟疾预防以来，由于其有效性，而且尤其是其低成本，因此主要依赖氯喹。 氯喹的抗性在世界不同地区已广泛。 甲氟喹和奎宁已在对氯喹的耐药性和前卫和治疗方面已广泛使用，但对这些药物的抗性已成为一个重大问题。 因此，需要更有效，更毒性的药物，尤其是利用途径和靶向寄生虫特有的理性药物。 恶性疟原虫是一种重要的关节肉毒内原生动物病原体，负责最严重的人类疟疾形式。 寄生虫在人类宿主中经历了许多发育阶段，并在红细胞中无性繁殖，以实现其临床症状和致命的结果。 我的实验室的研究重点是疟疾寄生虫如何应对不断变化的环境状况。 维持培养物中的寄生虫是我们研究的重要一步，以了解这种寄生虫的基本生物学以及疫苗或新抗疟药的未来开发。 GCRC通过抽血并将样本运送到研究实验室来支持研究。